MENU
Advertisement
Show Filters
Refine by Content Type
Refine by Year
Sort By:
Choose Sites to Search:
Transcatheter Aortic and Mitral Valve Update
The progress and promise of valvular interventions.
By Alain Cribier, MD; Vasilis Babaliaros, MD; and David Liff, MD
Aortic and Mitral Valves
By Ted E. Feldman, MD, FSCAI
An Interview With David G. Rizik, MD
How upcoming technology, devices, and research will benefit the interventional cardiology community.
Late Quality-of-Life Outcomes Are Similar for TAVR and SAVR in PARTNER II Analysis
November 1, 2016—Findings from the PARTNER II QUALITY OF LIFE study were presented at TCT 2016, the 28th annual Transcatheter Cardiovascular Therapeutics scientific symposium in Washington, DC. The study demonstrated that patients with severe aortic stenosis at intermediate surgical risk and who are treated with transcatheter aortic valve replacement (TAVR) had improved health status at 1 month compared with patients treated with surgical aortic valve replacement (SAVR), but 2-year quality-of-life (QoL) outcomes were similar. The background of the study is that previous studies have shown that TAVR provides an early QoL benefit in patients with severe aortic stenosis at high surgical risk; however, the effect of TAVR versus SAVR on QoL in intermediate-risk patients was unknown.
SYNTAX Compares Quality-of-Life Results for PCI With DES and CABG
March 17, 2011—In the New England Journal of Medicine, David J. Cohen, MD, et al have published findings from the SYNTAX (Taxus Drug-Eluting Stent Versus Coronary Artery Bypass Surgery for the Treatment of Narrowed Arteries) trial that investigated the quality-of-life effects of percutaneous coronary intervention (PCI) with the use of drug-eluting stents (2011;364:1016–1026). The SYNTAX study is sponsored by Boston Scientific Corporation (Natick, MA).
SYNTAX Investigates Quality-of-Life Results of PCI
March 17, 2011—In The New England Journal of Medicine, David J. Cohen, MD, et al have published findings from the SYNTAX (Taxus Drug-Eluting Stent Versus Coronary Artery Bypass Surgery for the Treatment of Narrowed Arteries) trial that investigated the quality-oflife effects of percutaneous coronary intervention (PCI) with the use of drug-eluting stents (2011;364:1016–1026). The SYNTAX study is sponsored by Boston Scientific Corporation (Natick, MA).
Edwards Sapien Valve Demonstrates Improved Quality of Life in Inoperable Patients
November 15, 2010—Edwards Lifesciences Corporation (Irvine, CA) announced that in addition to the improved survival seen in inoperable aortic stenosis patients treated with the Edwards Sapien transcatheter heart valve in the PARTNER trial, a newly released analysis of the same patients showed that they also experienced substantially better quality of life.
Sirolimus-Eluting Cypher Stent
A standard of comparison for drug-eluting stents.
By Colin M. Barker, MD, and David E. Kandzari, MD
The FAME Trial
Fractional flow reserve for target revascularization in multivessel PCI.
By Eric Yamen, MBBS, FRACP, and David P. Lee, MD
Radial Versus Femoral Access in PCI
An economic and quality analysis.
By Purushothaman Muthusamy, MD, and David H. Wohns, MD, FACC, FSCAI
Sponsored by Abiomed, Inc.
Developing a Protected PCI Program: Heart Team Approach at Spectrum Health
By David Wohns, MD, MBA, FACC, FSCAI
Xience V (Promus) Drug-Eluting Coronary Stent
Design features, preclinical data, and clinical outcomes.
By Krishna Sudhir, MD, PhD, FRACP, FACC; David R. Rutledge, Pharm D, FAHA, FCCP; Alena Pechonkina, MD; and Chuck Simonton, MD, FACC, FSCAI
Impact of CTO Angioplasty on Long-Term Clinical Outcomes
More data are needed to demonstrate the benefit of PCI for CTO.
By Renato Valenti, MD, and David Antoniucci, MD
Techniques for Percutaneous Revascularization of Coronary CTOs
Necessary skillsets for a hybrid approach to CTO PCI.
By Craig A. Thompson, MD, MMSc, and David V. Daniels, MD
Lessons From the TVT Registry
An assessment of the TVT registry, which is studying the real-world outcomes of patients undergoing new valvular therapies.
By David R. Holmes, MD, and Michael J. Mack, MD
Transcatheter Tricuspid Edge-to-Edge Repair for Severe Transplant-Related TR
Edge-to-edge repair for severe tricuspid regurgitation.
By David W.M. Muller, MBBS, MD
How to Implant the CardioMEMS Heart Failure Sensor
A step-by-step review of the sensor implantation procedure, including pre- and postprocedural assessment.
By David M. Shavelle, MD, FACC, FSCAI
New Insights From the STS/ACC TVT Registry
What these ongoing data tell us about TAVR and future areas of interest.
By Frederick L. Grover, MD, and David R. Holmes Jr, MD
Pathophysiology and Therapy for Atrial Septal Defects
An overview of this common congenital anomaly and the options for surveillance and treatment.
By Mary Shields, MD; Maria Baldasare, MD; David Goldberg, MD; Awail Sadiq, MD; and Sheldon Goldberg, MD, FACC, FSCAI
Update on Transcatheter Mitral Valve Repair
A look at the current and soon-to-come transcatheter mitral valve repair options.
By Dale J. Murdoch, MBBS; Robert H. Boone, MD; Robert Moss, MBBS; John Webb, MD; and David A. Wood, MD
